Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

MPE launches Horizon2020 CARAMBA video on CAR-T cell therapy in myeloma

At the recent European Haematology Association (EHA) Annual Congress 2018, Myeloma Patients Europe (MPE) and Video Journal of Hematological Oncology (VJHemOnc), filmed an interview with Dr Michael Hudecek (University of Würzburg, Germany) on the Horizon2020 CARAMBA project. MPE is collaborating with a consortium of European partners, including the University of Würzburg, on CARAMBA which is…

Read more

Myeloma Patients Europe (MPE) joins project consortium looking at the role of innovative CAR-T immunotherapy in multiple myeloma

Today marks the official launch of a new international project consortium, known as “CARAMBA”, which will research an innovative immunotherapy for the treatment of multiple myeloma, known as Chimeric Antigen Receptor T-cell therapy (CAR-T). Through strategic collaboration with a wide-range of stakeholders, the consortium aims to ensure the streamlined transition of CAR-T from the laboratory…

Read more

MPE will hold a webinar on ASH 2017 highlights in myeloma

Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2017. The talk will be given by Dr María Victoria Mateos, Associate Professor of Hematology and Consultant.…

Read more

ASH Annual Meeting 2017 is about to start

The 59th American Society of Hematology (ASH) Annual Meeting will take place from 9 – 12 December in Atlanta, Georgia, United States (US). Myeloma Patients Europe (MPE) will be attending the meeting, alongside thousands of leading doctors, researchers and patient advocates in the field of blood cancer (hematology). Below we explain ASH and the importance…

Read more

Promising results of CAR T-Cell therapy in myeloma patients

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of myeloma upon receiving a new type of immunotherapy  ̶  chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. The study was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual…

Read more
February

March 2026

April
MO
TU
WE
TH
FR
SA
SU
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Events for 1st March
No Events
Events for 2nd March
No Events
Events for 3rd March
No Events
Events for 4th March
No Events
Events for 5th March
No Events
Events for 6th March
No Events
Events for 7th March
No Events
Events for 8th March
No Events
Events for 9th March
No Events
Events for 10th March
No Events
Events for 11th March
No Events
Events for 12th March
No Events
Events for 13th March
No Events
Events for 14th March
No Events
Events for 15th March
No Events
Events for 16th March
No Events
Events for 17th March
No Events
Events for 18th March
No Events
Events for 19th March
No Events
Events for 20th March
No Events
Events for 21st March
No Events
Events for 22nd March
No Events
Events for 23rd March
No Events
Events for 24th March
No Events
Events for 25th March
No Events
Events for 26th March
No Events
Events for 27th March
No Events
Events for 28th March
No Events
Events for 29th March
No Events
Events for 30th March
No Events
Events for 31st March
No Events